2025 ahead ayondo Franchise coming soon
Happy 
xMas Holidays
xMas Holidays
xMas Holidays
Original-Research: Ikonisys SA - von Sphene Capital GmbH
Einstufung von Sphene Capital GmbH zu Ikonisys SA
Unternehmen: Ikonisys SA
ISIN: FR00140048X2
Anlass der Studie: Aufnahme der Coverage
Empfehlung: Buy
seit: 25.01.2022
Kursziel: EUR 7,70
Kursziel auf Sicht von: 24 Monate
Letzte Ratingänderung: -
Analyst: Peter Thilo Hasler, CEFA
Restart of a technology leader in laboratory automation
With a share price target of EUR 7.70 and an expected share price performance of 176.0%, we initiate research coverage on the shares of Ikonisys SA with a Buy rating. Our price target is derived from a threestage discounted cash flow entity model (primary valuation method), for which we calculate an equity value of EUR 7.70 per share in the base case scenario. In a Monte Carlo analysis, we have used alternative revenue, earnings and other key performance indicator scenarios and calculate equity values in a range between EUR and 6.10 per 9.20 share. An alternative economic profit model supports the results of the DCF model, while significantly higher price targets can be derived from peer group multiples (both secondary valuation methods).
Ikonisys is a provider of a robotic and software-based microscopy application that, according to the company, enables fully automated detection and quantification of rare and very rare cells in tissues and biological fluids. This is used in particular for cell diagnosis in oncology and genetic diseases. With the help of the FDA-approved Ikoniscope microscope, up to 2 million cells can be automatically scanned and analysed on a single slide without the manual involvement of laboratory staff. Ikonisys provides a range of diagnostic fluorescence in situ hybridisation (FISH) tests that can be used to visualise different types of cancer at an early stage using fluorescent tumour markers. We see considerable additional potential in the recently possible detection and characterisation of circulating tumour cells (CTCs) in liquid biopsies.
Ikonisys will generate one-off revenues from the production and sale of the Ikoniscope and recurring revenues from the sale of platform-optimised ownbrand probe kits, software applications and service agreements on the maintenance of the devices. Due to the pursued outsourcing of production, we estimate that expenses are mostly variable. We expect Ikonisys to generate its first significant revenues from microscope sales in 2022e. By 2026e, we expect revenues to rise to EUR 35.7m and the operating result (EBITDA) to just under EUR 10.0m in our base case scenario. The equity ratio of the virtually debt-free company should then be 85.3%.
Die vollständige Analyse können Sie hier downloaden: http://www.more-ir.de/d/23294.pdf
Kontakt für Rückfragen
Peter Thilo Hasler, CEFA
+49 (89) 74443558/ +49 (152) 31764553
peter-thilo.hasler@sphene-capital.de
-------------------übermittelt durch die EQS Group AG.-------------------
Für den Inhalt der Mitteilung bzw. Research ist alleine der Herausgeber bzw. Ersteller der Studie verantwortlich. Diese Meldung ist keine Anlageberatung oder Aufforderung zum Abschluss bestimmter Börsengeschäfte.
P R O D U C T S U G G E S T I O N S
The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.
The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.
If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.
For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.
1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.
